FTC v Actavis

The U.S. Supreme Court heard oral arguments yesterday regarding a case of addressing the question of whether “reverse payments” made by a patent holding pharmaceutical company to a generic drug company for not entering the market for a patented drug runs afoul of anti-trust law. ¬†Here is the transcript¬†FTC v Actavis